CVS Health Embraces Yeztugo: A Major Stride in HIV Prevention

In a significant move for public health, CVS Health, one of the leading pharmacy benefit managers in the United States, has made the decision to cover Yeztugo, a new and revolutionary HIV prevention medication. This decision comes after extensive advocacy and is welcomed as a major advancement in the ongoing battle against HIV.

Yeztugo, which was approved by the U.S. Food and Drug Administration in June 2025, represents a groundbreaking approach to HIV prevention. It is the first Pre-Exposure Prophylaxis (PrEP) medication that can be administered via injection, with the unique advantage of only needing to be taken once every six months. This reduced dosing schedule is expected to enhance adherence and accessibility, making it a promising tool in the efforts to curb the HIV epidemic.

Advocacy and Change

"We are thrilled that CVS Health has finally chosen to cover this transformative PrEP medication," said Carl Schmid, the executive director of the HIV+ Hepatitis Policy Institute. The decision follows persistent efforts by advocacy groups. Four months earlier, a coalition of 63 HIV organizations, led by Schmid’s institute, had sent a formal letter to CVS, urging them to reconsider their stance on Yeztugo. The coalition highlighted CVS's obligations to cover PrEP under existing health care policies and emphasized the drug's potential impact on reducing HIV transmission rates in the United States.

Schmid noted that CVS Health's inclusion of Yeztugo in their coverage aligns them with other major pharmacy benefit managers and insurers who have also embraced the drug. According to data from Gilead Sciences, the pharmaceutical company responsible for developing Yeztugo, about 85% of insured Americans now have access to this medication.

Access and Affordability

However, while coverage is a major step forward, it does not automatically ensure access for all who need it. Schmid pointed out the ongoing challenges many people face, such as copayments and limited coverage options. "Even with insurance, too many individuals are struggling with copays, and some plans, including employer-based ones, are not covering all PrEP options," he stated. This highlights the necessity for continued advocacy to ensure that financial barriers do not hinder access to PrEP medications, like Yeztugo, that can significantly reduce new HIV infections.

Ongoing Efforts and Government Role

To address these issues, the HIV+ Hepatitis Policy Institute is collaborating with other advocacy organizations to urge both federal and state governments to enforce insurance coverage for PrEP more rigorously. They are calling for sustained investment in HIV prevention programs at state and local levels, which are crucial for supporting community-based initiatives and ensuring that preventative measures reach all populations at risk.

Schmid emphasized the importance of "aggressive enforcement of PrEP insurance coverage requirements" to hold insurers accountable. He also advocated for "sustained funding of state, local, and community HIV prevention programs," which are essential components in the comprehensive strategy to eliminate HIV as a public health threat.

In conclusion, CVS Health's decision to cover Yeztugo is a promising development in the fight against HIV, but it is just one part of a broader effort needed to ensure everyone has access to life-saving prevention tools. As the healthcare landscape continues to evolve, advocacy groups remain vigilant in their mission to ensure equitable access and eliminate the barriers that prevent individuals from receiving the care they need.